Yeah, tell that to CELG... guess you have done little homework yourself. TELK's Telintra works so well it made a peer reviewed medical journal on the Phase II trial it was partnered with CLEG's drug in. Look what CELG trades at and it's CELG's biggest money product.
I have no beef with you East. Just seems like you want everyone to be forced to agree with you?
Actually they have corporate finance options as well... same as all little bio companies. Like the post says most are cash strapped and when they get a game changer as far as the start of Phase III the funding comes.
This is a message board people already know you need to use due diligence.
Volume up on a Friday speaks volumes... the "hype cycle" that is typical of the early stage bio company (entering Phase III trials) seems to be here with Telik. Typical of bio's about to breakout are the relatively recent frenzy, followed by a period of selling and then apathy, what happens next though is recovery and finally the "new extended breakout". This is the time investors likely make a move and in TELK's case the move does seem warranted.
The main thing in common with little bio's noticed are the sell off's after the initial spike on "real" news. Telik's news about Telintra and its progression to Phase III appears to qualify as "real" news. These bios companies tend to need to raise capital and TELK is no different however they seem to find the way once possessing something other corporations will be interested in. Telintra qualifies for TELK as something others will be interested in. Unlike past sell offs these small bio's are followed with sustained volume and as someone pointed out lots of "inter-market sweep orders" aggressively buying up the float.
Someone believes in the long-term prospect of TELK wake-up call for small bio investors and Monday is certainly going to give time to get in at compelling prices. The coming climb has yet to start and won't be scratching the surface till it's up a few dollars from the current valuation.
Telik will no longer trade like it used to, this time it's a climber that will hold just as a speculative small bio should.